Newborn Screening Market Size to Exceed USD 4,094.9 Mn by 2032

The Newborn Screening Market, estimated at USD 1,997.4 Mn in 2025, is expected to exhibit a CAGR of 10.8% and reach USD 4,094.9 Mn by 2032.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

Increasing newborn screening programs by the government will drive the global newborn screening market. For instance, on September 18, 2025,  the Colorado Department of Public Health and Environment celebrates September as Newborn Screening Awareness Month. The Colorado Newborn Blood Spot Screening Program at the Colorado Department of Public Health and Environment’s State Public Health Laboratory is observing Newborn Screening Awareness Month by raising awareness about the importance of newborn screening.

Global Newborn Screening Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.

COVID-19 had a negative impact on the global newborn screening market. For instance, on April 11, 2025, according to an article published in the International Journal of Neonatal Screening, Newborn Screening, a Pandemic—Lessons Learned, the COVID-19 pandemic affected many essential aspects of public health, including newborn screening programs (NBS).

Global Newborn Screening Market: Key Developments

On November 14, 2025, Revvity Inc. (PerkinElmer Inc.) a global technology provider announced that the U.S. Food and Drug Administration (FDA) had authorized the marketing of the EONIS SCID-SMA assay kit for in vitro diagnostic (IVD) for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. It is the first FDA-authorized assay for SMA screening in newborns in the U.S. and is part of the company’s broader EONIS platform.

Browse 36 Market Data Tables and 26 Figures spread through 210 Pages and in-depth TOC on “Global Newborn Screening Market”- Forecast to 2032, Global Newborn Screening Market, By Product (Instruments, Assay Kits and Reagents), By Test Type (Dry Blood Spot Test, Cardiac Test, Hearing Test, Urine Test and Others), By Application (Phenylketonuria, Critical Congenital Cardiac Disease, Maple Syrup Urine Disease, Hearing Disability, Sickle Cell Disease and Others), By End User (Hospital, Maternity and Specialty Clinics and Diagnostic Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/newborn-screening-market-2192

Key Takeaways of the Global Newborn Screening Market:

• The global newborn screening market is expected to exhibit a CAGR of 10.8% during the forecast period. The collaboration with market players offers lucrative growth opportunities for players in the global newborn screening market.
• Among application, the sickle cell disease segment is expected to hold a dominant position in the global newborn screening market during the forecast period, and this is attributed to the collaboration of market players for increasing capacity for newborn screening of sickle cell disease. For instance, in June 2025, Revvity Inc. (PerkinElmer Inc.) collaborated with the American Society of Hematology (ASH), the world's largest professional society of hematologists, to support a new effort to increase capacity for newborn screening, education, and clinical interventions for sickle cell disease (SCD) in sub-Saharan Africa. This collaboration enhances screening networks, education, clinical intervention, and advocacy for newborn screening.
• Among regions, the North America region is expected to have dominant position in the global newborn screening market, owing to the increasing birth defects with child. For instance, accoding to article published in Jama Network in April 2025, a “Association of Birth Defects With Child Mortality Before Age 14 Years”, states that among the 1,037,688 children in the cohort 95,566 had birth defects.
• Major players operating in the global newborn screening market are Agilent Technologies, Inc., Bio-rad laboratories, Inc., Medtronic Plc, Masimo Corporation, Natus Medical Inc., Perkin Elmer, Inc, ZenTec S.A., Trivitron Healthcare Pvt Ltd, Waters Technologies Corporation, Danaher Corporation, Baebies, Inc , Parseq Lab Co. Ltd , Chromesystem Instruments and Chemicals GmbH , and RECIPE Chemicals+ Instrument GmbH